Researchers at the University of California – Davis investigated a novel drug, MYK-461, that proved effective in altering feline heart function in naturally occurring inherited hypertrophic cardiomyopathy (HCM).  The data suggest that cats may serve as an effective model where mouse models have been limited in the evaluation of new treatments for HCM patients with left ventricular outflow tract (LVOT) obstruction.

Investigators

  • Joshua Stern, DVM, PhD
  • Eric Green, MD
  • Samantha Harris, PhD

Three key benefits to the findings

  • Provides proof of principle that a sarcomere inhibitor can acutely relieve provocable LVOT gradients in cats with HCM
  • Paves the way for chronic studies in animals and humans
  • Results highlight the value of companion animals in translational research and raise the potential of a novel therapeutic approach in HCM patients
Treatment abolished mitral valve systolic anterior motion and reduced left ventricular outflow tract gradients in cats with hypertrophic cardiomyopathy